Vertex Pharmaceuticals Inc

2026. g. 12. nov. 20:56 UTC

Vertex Pharmaceuticals shares are declining amid a broader downturn in the biotechnology sector, influenced by significant drops in key holdings like Moderna and Regeneron.

2026. g. 11. nov. 22:51 UTC

Vertex Pharmaceuticals shares are trading modestly lower during after-market hours, aligning with broader market declines amid rising U.S. Treasury yields and inflation concerns.

2026. g. 10. nov. 22:41 UTC

Vertex Pharmaceuticals is gaining significantly in after-market trading, sitting well above its 20-day moving average and near the upper end of its one-month range.

2026. g. 9. nov. 23:01 UTC

Vertex Pharmaceuticals shares are declining in after-market trading, continuing a downward trend that began shortly after the market closed.

2026. g. 6. nov. 23:06 UTC

Vertex Pharmaceuticals shares advanced during after-market hours on Friday, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. g. 5. nov. 23:22 UTC

Vertex Pharmaceuticals is declining in after-market trading, influenced by broader market concerns and a drop in the iShares Biotechnology ETF (IBB).

2026. g. 4. nov. 21:04 UTC

Barclays raises Vertex Pharmaceuticals' price target to $626.00 from $617.00 while maintaining an Overweight rating, as shares advance amid broader Biotechnology sector gains.

2026. g. 3. nov. 21:03 UTC

Vertex Pharmaceuticals' stock is declining after a profit drop to $653.6 million and adjusted EPS of $4.76, missing estimates amid rising operational costs.

2026. g. 2. nov. 23:02 UTC

Vertex Pharmaceuticals reported Q3 revenue of $3.44 billion, raised full-year guidance to $13.15 billion-$13.25 billion, and completed the acquisition of Crinetics Pharmaceuticals.

2026. g. 30. okt. 23:26 UTC

Vertex Pharmaceuticals shares advanced modestly in after-market trading, recovering from earlier losses and surpassing Friday's close amid increased momentum.

2026. g. 29. okt. 23:03 UTC

Vertex Pharmaceuticals is trading higher in after-market hours, rebounding from an earlier session low to surpass Thursday's close significantly.

2026. g. 28. okt. 22:03 UTC

Vertex Pharmaceuticals is trading higher in after-market hours, having advanced significantly since Wednesday's close and reached a session high.

2026. g. 27. okt. 23:36 UTC

Vertex Pharmaceuticals is set to report Q3 FY2026 earnings on November 2, with estimated EPS of $0.94 and expected revenue of $3.4 billion.

2026. g. 26. okt. 20:02 UTC

Vertex Pharmaceuticals announces Phase 3 RAINIER results for povetacicept published in the New England Journal of Medicine, with data presented at Kidney Week 2026.

2026. g. 23. okt. 20:08 UTC

Vertex Pharmaceuticals published positive Phase 3 RAINIER results for povetacicept in IgA nephropathy and received FDA acceptance for a Biologics License Application.

2026. g. 22. okt. 23:46 UTC

Vertex Pharmaceuticals Inc shares have seen a slight decline during after-market trading, remaining roughly flat since Thursday's close.

2026. g. 21. okt. 23:01 UTC

Vertex Pharmaceuticals Inc is declining in after-market trading, currently at its lowest point of the day following a sharp drop since Wednesday's close.

2026. g. 20. okt. 23:11 UTC

Vertex Pharmaceuticals Inc is trading lower in after-market hours, having declined since Tuesday's close, despite a brief early-session gain.

2026. g. 19. okt. 22:16 UTC

Vertex Pharmaceuticals Inc shares are modestly higher in after-market trading following fluctuations during the session and a notable decline from earlier peaks.

2026. g. 16. okt. 20:07 UTC

Vertex Pharmaceuticals Inc shares are declining, reversing from an earlier session high and remaining below their 20-day moving average, significantly lower than Thursday's close.

2026. g. 15. okt. 20:03 UTC

Vertex Pharmaceuticals has completed its $10 billion acquisition of Crinetics Pharmaceuticals, contributing to higher shares amid strong performance in the Biotechnology sector.

2026. g. 14. okt. 23:31 UTC

Vertex Pharmaceuticals Inc. is trading modestly higher in after-market hours, recovering from an earlier retreat, and has risen since Wednesday's close.

2026. g. 13. okt. 20:01 UTC

Vertex Pharmaceuticals Inc shares are declining, marked by a significant drop from the opening price and reaching the lowest point of the session.

2026. g. 12. okt. 20:06 UTC

Vertex Pharmaceuticals Inc shares are modestly lower, settling near the lower end of their one-month range and below the 20-day moving average.

2026. g. 9. okt. 20:07 UTC

Vertex Pharmaceuticals presents promising interim data from its ALYFTREK study, showing potential reversal of pancreatic insufficiency in some children with cystic fibrosis.

2026. g. 8. okt. 20:07 UTC

RBC Capital raised the price target on Vertex Pharmaceuticals to $576 from $560 while maintaining an Outperform rating.

2026. g. 7. okt. 19:55 UTC

Vertex Pharmaceuticals Inc is trading modestly higher, having reached an intraday high before retracing, though it remains below its 20-day moving average.

2026. g. 6. okt. 20:06 UTC

Vertex Pharmaceuticals Inc shares are declining amid a broader downturn in the biotechnology sector, marked by five consecutive sessions of losses.

2026. g. 5. okt. 20:06 UTC

Vertex Pharmaceuticals Inc shares fell, continuing a trend of four consecutive sessions lower, despite earlier peaks in the current session.

2026. g. 2. okt. 20:07 UTC

Vertex Pharmaceuticals Inc shares fell to their lowest level since August 2026, reflecting a decline since Thursday's close amid broader market losses.